Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid

Clinical Lung Cancer
Lee M KrugWm Kevin Kelly

Abstract

Histone deacetylase inhibitors are a novel class of therapeutic agents that inhibit deacetylate histones and other proteins involved in the regulation of gene expression and cell cycle progression. Phase I trials of intravenous and oral formulations of one such agent, vorinostat (suberoylanilide hydroxamic acid [SAHA]), have shown that it is safe and tolerable, that it inhibits histone deacetylation in peripheral blood mononuclear cells, and that it has a broad range of antitumor activity. Thirteen patients with mesothelioma were included in a phase I trial of oral SAHA. All but one had previously been treated with chemotherapy. Four patients completed > or = 6 cycles of therapy; 2 patients demonstrated a partial response. The toxicities in this cohort of patients were similar to those observed in the entire phase I trial: primarily fatigue, dehydration, nausea, and vomiting. Given the dearth of treatment options for patients with advanced mesothelioma who have progressed after first-line chemotherapy, these results are encouraging. A placebo-controlled, randomized phase III study of oral SAHA is now open for patients with mesothelioma in whom treatment with pemetrexed has failed.

References

Nov 20, 2001·American Journal of Respiratory Cell and Molecular Biology·X X CaoW R Smythe
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stanislaw M MikulskiKuslima Shogen
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K FizaziP Ruffié
Mar 22, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G GiacconeB Smit
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicholas J VogelzangPaolo Paoletti
Feb 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J Byrne, A K Nowak
Feb 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Harvey I PassSorin Draghici
Mar 2, 2005·Proceedings of the National Academy of Sciences of the United States of America·Melissa J PeartRicky W Johnstone
Mar 25, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ramaswamy GovindanUNKNOWN Cancer and Leukemia Group B (CALGB 30101)
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Kevin KellyVictoria M Richon
Dec 6, 2005·Hematology/oncology Clinics of North America·Lee M Krug

❮ Previous
Next ❯

Citations

Sep 5, 2008·Current Treatment Options in Oncology·Hedy Lee Kindler
Jun 3, 2009·Journal of Hematology & Oncology·Shundong CangDelong Liu
Jul 29, 2009·Journal of Hematology & Oncology·David SiegelSyed Rizvi
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suresh S RamalingamChandra P Belani
Jun 1, 2011·Cancer Management and Research·Nadine Martinet, Philippe Bertrand
Apr 21, 2009·Future Oncology·Rolf A StahelWalter Weder
Mar 14, 2012·Future Oncology·Federica Grosso, Giorgio Vittorio Scagliotti
May 5, 2009·Expert Opinion on Therapeutic Targets·Rayleen V BowmanKwun M Fong
Apr 21, 2009·Expert Review of Anticancer Therapy·Paolo Andrea ZucaliArmando Santoro
Feb 10, 2007·Expert Review of Anticancer Therapy·Joseph G Sinkovics
Mar 28, 2008·Expert Review of Anticancer Therapy·Walid RasheedH Miles Prince
Mar 16, 2007·Expert Opinion on Emerging Drugs·Giorgio Vittorio Scagliotti, Giovanni Selvaggi
Apr 28, 2007·Expert Opinion on Investigational Drugs·Walid K RasheedH Miles Prince
Nov 4, 2011·Expert Opinion on Investigational Drugs·L Rhoda Molife, Johann S de Bono
Dec 26, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Paul K Paik, Lee M Krug
Aug 26, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Sarita DubeyHedy Lee Kindler
Jan 31, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·James SymanowskiSunil Sharma
Sep 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Suresh S Ramalingam, Chandra P Belani
Apr 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Robert A KratzkeUNKNOWN Cancer and Leukemia Group B
Dec 20, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Suresh S RamalingamDavid Gandara
Feb 28, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Steven G GrayKenneth J O'Byrne
Apr 7, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Anne M TraynorJoan H Schiller
Jun 25, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Fabian VandermeersLuc Willems
May 31, 2011·Trends in Pharmacological Sciences·Roberto E Favoni, Tullio Florio
Feb 4, 2011·Cancer Treatment Reviews·P A ZucaliA Santoro
May 15, 2010·Critical Reviews in Oncology/hematology·Jan P van MeerbeeckPaul Baas
Nov 3, 2009·Cancer Treatment Reviews·Giovanni Luca CeresoliArmando Santoro
Oct 14, 2009·Seminars in Thoracic and Cardiovascular Surgery·David M Jackman
Dec 23, 2015·Clinical Epigenetics·Clara NerviGiovanni Codacci-Pisanelli
Sep 13, 2007·Molecular Carcinogenesis·Colleen C SpurlingCharles Giardina
Jan 30, 2009·Journal of Cellular and Molecular Medicine·M W LawlessS G Gray
Sep 18, 2007·Angewandte Chemie·Arturo J VegasStuart L Schreiber
Feb 18, 2010·Medicinal Research Reviews·Eleni Pontiki, Dimitra Hadjipavlou-Litina
Jul 21, 2006·Biochemical Pharmacology·Michèle J HoffmannWolfgang A Schulz
Aug 15, 2006·Bioorganic & Medicinal Chemistry Letters·Cédric CharrierJoëlle Roche
Jul 2, 2010·Journal of Receptor and Signal Transduction Research·Peter Kovacic, Corey L Edwards
Jan 2, 2013·Cancer Treatment Reviews·Jordi RemonMontserrat Zanui
Sep 26, 2007·Genetic Vaccines and Therapy·Blanca Segura-PachecoGustavo Cabrera
Nov 28, 2012·Nanomedicine : Nanotechnology, Biology, and Medicine·Melissa S WasonCheryl H Baker
May 31, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Ronan Joseph KellyRaffit Hassan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Birth Defects Research. Part B, Developmental and Reproductive Toxicology
L David WiseJanet S Kerr
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Quang T LuongH Phillip Koeffler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Nichole Boyer ArnoldMurray Korc
© 2021 Meta ULC. All rights reserved